Compare GSK plc (GSK) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wheaton Precious Metals Corp — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Wheaton Precious Metals Corp trades at $138.57 (market cap $61.17B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Wheaton Precious Metals Corp for 66 Days on average.
| GSK | WPM | |
|---|---|---|
Market Cap | $91.88B | $61.17B |
Volume | 7,730,529 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $165.72 |
52-Week Low | $43.24 | $94.37 |
Typical Hold Time | 93 Days | 66 Days |
Enterprise Value | $111.88B | $63.05B |
Dividend Yield | 3.9% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
WPM trades at $138.65, up 3.71% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported record 2025 revenue of $2.31B and net income of $1.47B, with earnings beating estimates in recent quarters. Analyst consensus is strongly bullish with an 80% buy rating and a $164.80 price target. Recent news highlights production growth targets of 1.2M ounces by 2030 and a fully funded pipeline.
The outlook for WPM is positive given robust earnings growth, high profitability margins, and strategic expansion plans. Key risks include execution of growth targets, commodity price volatility, and interest rate sensitivity. The stock offers upside to consensus targets but faces technical resistance near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
